DCM
STRO icon

DAFNA Capital Management’s Sutro Biopharma STRO Stock Holding History

DAFNA Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-43,708
Closed -$380K – 86
2025
Q3 		$380K Hold
43,708
– – 0.09% 72
2025
Q2 		$312K Hold
43,708
– – 0.09% 71
2025
Q1 		$284K Hold
43,708
– – 0.08% 77
2024
Q4 		$804K Buy
43,708
+10,750
+33% +$328K 0.2% 65
2024
Q3 		$1.14M Hold
32,958
– – 0.27% 60
2024
Q2 		$966K Sell
32,958
-450
-1% -$17.8K 0.23% 62
2024
Q1 		$1.89M Buy
33,408
+5,100
+18% +$225K 0.43% 47
2023
Q4 		$1.21M Hold
28,308
– – 0.29% 58
2023
Q3 		$982K Buy
28,308
+4,030
+17% +$176K 0.31% 57
2023
Q2 		$1.13M Buy
24,278
+15,808
+187% +$787K 0.31% 50
2023
Q1 		$391K Buy
+8,470
New +$538K 0.12% 63
2022
Q4 		– Sell
-8,120
Closed -$451K – 84
2022
Q3 		$451K Sell
8,120
-350
-4% -$20.7K 0.12% 73
2022
Q2 		$441K Hold
8,470
– – 0.12% 78
2022
Q1 		$696K Buy
8,470
+3,970
+88% +$378K 0.18% 78
2021
Q4 		$670K Sell
4,500
-4,000
-47% -$717K 0.17% 76
2021
Q3 		$1.61M Hold
8,500
– – 0.43% 55
2021
Q2 		$1.58M Hold
8,500
– – 0.33% 58
2021
Q1 		$1.94M Hold
8,500
– – 0.46% 52
2020
Q4 		$1.84M Sell
8,500
-3,394
-29% -$562K 0.55% 40
2020
Q3 		$1.2M Buy
11,894
+1,250
+12% +$118K 0.39% 53
2020
Q2 		$826K Buy
10,644
+6,644
+166% +$638K 0.24% 64
2020
Q1 		$408K Hold
4,000
– – 0.17% 68
2019
Q4 		$440K Hold
4,000
– – 0.15% 73
2019
Q3 		$364K Buy
4,000
+851
+27% +$85.9K 0.14% 76
2019
Q2 		$358K Hold
3,149
– – 0.13% 75
2019
Q1 		$359K Hold
3,149
– – 0.15% 68
2018
Q4 		$284K Buy
3,149
+400
+15% +$48.3K 0.14% 72
2018
Q3 		$412K Buy
+2,749
New +$415K 0.17% 62

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

DAFNA Capital Management's STRO Position: Q4 2025 in Review

DAFNA Capital Management sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 43,708 shares — an estimated $380K sold.

DAFNA Capital Management first reported a position in STRO in Q3 2018 and held it in 28 quarters. The position peaked at $1.94M in Q1 2021. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • DAFNA Capital Management reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • DAFNA Capital Management sold 43,708 Sutro Biopharma shares in Q4 2025, an estimated $380K.
  • DAFNA Capital Management first reported a position in Sutro Biopharma in Q3 2018 and held it in 28 quarters.
  • DAFNA Capital Management's Sutro Biopharma position peaked at $1.94M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.